• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Diabetes

Embecta Q3 results beat analyst expectations 

August 10, 2026 By drugdelivery

This is the logo of Embecta.

Julia Rock-Torcivia Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June […]

Filed Under: Diabetes, Drug-Device Combinations, MassDevice Earnings Roundup, Wall Street Beat Tagged With: embecta

Senseonics more than doubles Q2 revenue in post-Ascensia era

August 7, 2026 By Chris Newmarker

Senseonics Eversense 365 CGM implant fingers

Senseonics  (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […]

Filed Under: Business/Financial News, Diabetes, Featured, MassDevice Earnings Roundup Tagged With: Senseonics

6 diabetes tech companies you need to know

August 7, 2026 By Sean Whooley

Sequel MedTech twiist automated insulin pump with FreeStyle Libre sensor worn on arm

You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: Glucotrack, modularmedical, PharmaSens, Portal Diabetes, Sequel Med Tech, ViCentra

Tandem Diabetes Care seeing early benefits of new pay-as-you-go model

August 7, 2026 By Chris Newmarker

This is the logo of Tandem Diabetes Care.

Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that’s been rolling out this year. According to the San Diego–based company’s second-quarter report, released after market close yesterday, the alternative reimbursement structure, available through patients’ pharmacy benefits rather than medical benefits, eliminates upfront pump […]

Filed Under: Business/Financial News, Diabetes, Featured, MassDevice Earnings Roundup, Uncategorized Tagged With: Tandem Diabetes Care

The 10 largest diabetes tech companies in the world in 2026

August 6, 2026 By Sean Whooley

Medtronic MiniMed 780G with Simplera Sync Sensor worn on arm diabetes

Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Beta Bionics, Dexcom, embecta, Insulet, minimed, MyLife Diabetes Care, Roche, Senseonics, Tandem Diabetes Care, Ypsomed

Diabetes Technology Innovations Special Report — 2026

August 5, 2026 By Sean Whooley

MiniMed 780G worn with Simplera Sync

Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Beta Bionics, Dexcom, embecta, Insulet, minimed, MyLife Diabetes Care, Roche, Roche Diabetes Care, Senseonics, Tandem Diabetes Care

Insulet slightly lowers 2026 sales growth outlook despite Q2 beats

August 5, 2026 By Sean Whooley

Insulet logo

Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However,  it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Insulet

Modular Medical to initiate first phase of Pivot pump launch in October

August 4, 2026 By Sean Whooley

Modular Medical Pivot Insulin Patch Pump Product Image

Modular Medical (Nasdaq:MODD) announced its plans to initiate the first phase of the launch of its Pivot tubeless insulin patch pump. Pivot, designed to make insulin pump therapy simpler to learn and easier to live with, features a removable, two-part design and a 3 mL reservoir, intuitive interface and flexible, wearable form factor. The system […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: modularmedical

Dexcom Q2 results beat expectations, lead to increased sales outlook

July 30, 2026 By Sean Whooley

Dexcom Stelo user chops food

Dexcom (Nasdaq:DXCM) today reported second-quarter results that came in ahead of the consensus Wall Street forecast. Shares of DXCM rose 2% to $76.02 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three […]

Filed Under: Business/Financial News, Diabetes, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

GLP-1 therapies delivered by Stevanato Group pen injectors get green light in Europe

July 30, 2026 By Sean Whooley

Stevanato Group Alina pen injector

Stevanato Group announced today that liraglutide products incorporating its Alina pen injector received marketing authorization in Europe. Approved liraglutide-based combination products include Alina 30, developed for these therapies for diabetes, as well as Alina 50 for weight management applications. Both variants come as part of the company’s broader Alina variable-dose pen injector platform. The platform […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: Stevanato Group

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 203
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS